JP6948265B2 - クラステリンアイソフォームの特異的検出 - Google Patents

クラステリンアイソフォームの特異的検出 Download PDF

Info

Publication number
JP6948265B2
JP6948265B2 JP2017556249A JP2017556249A JP6948265B2 JP 6948265 B2 JP6948265 B2 JP 6948265B2 JP 2017556249 A JP2017556249 A JP 2017556249A JP 2017556249 A JP2017556249 A JP 2017556249A JP 6948265 B2 JP6948265 B2 JP 6948265B2
Authority
JP
Japan
Prior art keywords
crusterin
specific
kidney
specifically bind
isoform
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017556249A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018515762A5 (enExample
JP2018515762A (ja
Inventor
ジョセフ クウィン，ジョン
ジョセフ クウィン，ジョン
イェラミッリ，マーシー，ヴイエスエヌ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idexx Laboratories Inc
Original Assignee
Idexx Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idexx Laboratories Inc filed Critical Idexx Laboratories Inc
Publication of JP2018515762A publication Critical patent/JP2018515762A/ja
Publication of JP2018515762A5 publication Critical patent/JP2018515762A5/ja
Priority to JP2021012877A priority Critical patent/JP2021099342A/ja
Application granted granted Critical
Publication of JP6948265B2 publication Critical patent/JP6948265B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G01N33/521—Single-layer analytical elements
    • G01N33/523—Single-layer analytical elements the element being adapted for a specific analyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/415—Assays involving biological materials from specific organisms or of a specific nature from plants
    • G01N2333/42—Lectins, e.g. concanavalin, phytohaemagglutinin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2017556249A 2015-04-30 2016-04-29 クラステリンアイソフォームの特異的検出 Active JP6948265B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021012877A JP2021099342A (ja) 2015-04-30 2021-01-29 クラステリンアイソフォームの特異的検出

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562155175P 2015-04-30 2015-04-30
US62/155,175 2015-04-30
PCT/US2016/030075 WO2016176565A1 (en) 2015-04-30 2016-04-29 Specific detection of clusterin isoforms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021012877A Division JP2021099342A (ja) 2015-04-30 2021-01-29 クラステリンアイソフォームの特異的検出

Publications (3)

Publication Number Publication Date
JP2018515762A JP2018515762A (ja) 2018-06-14
JP2018515762A5 JP2018515762A5 (enExample) 2019-05-16
JP6948265B2 true JP6948265B2 (ja) 2021-10-13

Family

ID=56069221

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017556249A Active JP6948265B2 (ja) 2015-04-30 2016-04-29 クラステリンアイソフォームの特異的検出
JP2021012877A Pending JP2021099342A (ja) 2015-04-30 2021-01-29 クラステリンアイソフォームの特異的検出

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021012877A Pending JP2021099342A (ja) 2015-04-30 2021-01-29 クラステリンアイソフォームの特異的検出

Country Status (12)

Country Link
US (1) US20180142009A1 (enExample)
EP (2) EP4019976A1 (enExample)
JP (2) JP6948265B2 (enExample)
KR (1) KR102462056B1 (enExample)
CN (1) CN108093648B (enExample)
AU (1) AU2016254150B2 (enExample)
CA (1) CA2983828A1 (enExample)
DK (1) DK3289363T3 (enExample)
ES (1) ES2907068T3 (enExample)
MX (1) MX388832B (enExample)
WO (1) WO2016176565A1 (enExample)
ZA (1) ZA201707313B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021099342A (ja) * 2015-04-30 2021-07-01 アイデックス ラボラトリーズ インコーポレイテッドＩＤＥＸＸ Ｌａｂｏｒａｔｏｒｉｅｓ， Ｉｎｃ． クラステリンアイソフォームの特異的検出

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3232200A1 (en) 2016-04-12 2017-10-18 Institut Catalá De Ciencies Cardiovasculars (ICCC) Methods and kits for the diagnosis and risk stratification of patients with ischemia
FR3069156B1 (fr) 2017-07-21 2019-08-09 Universite de Bordeaux Clusterine pour son utilisation dans le traitement des micro-angiopathies thrombotiques
CN109239362B (zh) * 2018-10-22 2021-05-07 西北大学 一种凝集素探针组合在基于尿蛋白糖型鉴别秦岭川金丝猴妊娠方面的应用
CN110045127A (zh) * 2019-04-03 2019-07-23 中国医学科学院北京协和医院 一种IgG4相关性疾病多器官受累的生物标志物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
JP2714664B2 (ja) * 1988-04-13 1998-02-16 塩野義製薬株式会社 マイコプラズマ由来マクロファージ活性化因子
US5726010A (en) 1991-07-31 1998-03-10 Idexx Laboratories, Inc. Reversible flow chromatographic binding assay
WO2004005934A2 (en) * 2002-07-04 2004-01-15 Oxford Glycosciences (Uk) Ltd Toxicity markers
ITRM20040098A1 (it) * 2004-02-25 2004-05-25 Univ Roma Anticorpi oligoclonali anticlasterina per la diagnosi di neoplasie e la predizione del loro grado di malignita', metodo diagnostico e kit relativi.
EP1877796A2 (en) * 2005-05-05 2008-01-16 Philadelphia Health & Education Corporation d/b/a Diagnosis of liver pathology through assessment of protein glycosylation
EP2913676A1 (en) * 2008-11-10 2015-09-02 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US8168396B2 (en) * 2009-05-11 2012-05-01 Diabetomics, Llc Methods for detecting pre-diabetes and diabetes using differential protein glycosylation
US9551720B2 (en) * 2011-01-26 2017-01-24 University of Pittsburgh—Of the Commonwaelth System of Higher Education Urine biomarkers for prediction of recovery after acute kidney injury: proteomics
US20160146832A1 (en) * 2013-06-05 2016-05-26 Lakhmir S. Chawla Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN104267187A (zh) * 2014-10-15 2015-01-07 吉林大学 检测尿液Clusterin含量试纸条的制备及应用
DK3289363T3 (da) * 2015-04-30 2022-02-28 Idexx Lab Inc Specifik påvisning af clusterin isoformer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021099342A (ja) * 2015-04-30 2021-07-01 アイデックス ラボラトリーズ インコーポレイテッドＩＤＥＸＸ Ｌａｂｏｒａｔｏｒｉｅｓ， Ｉｎｃ． クラステリンアイソフォームの特異的検出

Also Published As

Publication number Publication date
AU2016254150A1 (en) 2017-10-26
KR20180003549A (ko) 2018-01-09
NZ736200A (en) 2021-11-26
EP3289363A1 (en) 2018-03-07
CN108093648A (zh) 2018-05-29
AU2016254150B2 (en) 2021-09-30
CA2983828A1 (en) 2016-11-03
ES2907068T3 (es) 2022-04-21
US20180142009A1 (en) 2018-05-24
MX2017013729A (es) 2018-05-22
ZA201707313B (en) 2022-02-23
JP2021099342A (ja) 2021-07-01
EP4019976A1 (en) 2022-06-29
BR112017021850A2 (pt) 2018-07-10
EP3289363B1 (en) 2021-11-24
CN108093648B (zh) 2020-04-10
DK3289363T3 (da) 2022-02-28
MX388832B (es) 2025-03-20
KR102462056B1 (ko) 2022-11-02
WO2016176565A1 (en) 2016-11-03
JP2018515762A (ja) 2018-06-14

Similar Documents

Publication Publication Date Title
JP2021099342A (ja) クラステリンアイソフォームの特異的検出
JP6861771B2 (ja) 腎疾患のためのマーカー
US12385925B2 (en) Anti-VLA-4 related assays
KR20210013646A (ko) 바이러스 및 박테리아 감염의 복합 검출을 위한 방법 및 장치
JP2018515762A5 (enExample)
JPWO2015019979A1 (ja) 統合失調症に関するバイオマーカー
KR101495225B1 (ko) Ast 양의 측정을 통한 간 질환 진단, 예후 또는 모니터링 키트 및 방법
JP6438474B2 (ja) 非グリコシル化ｓｕＰＡＲバイオマーカー及びその使用
WO2012153773A1 (ja) 可溶性ｌｒ１１の免疫学的測定方法
US8697368B2 (en) Diagnostic marker for lung cancer comprising HPαR as active ingredient
BR112017021850B1 (pt) Métodos para detectar clusterina específica do rim, doença renal, insuficiência renal ou danos nos rins, para distinguir mais uma isoforma de clusterina a partir de outros tipos de isoformas dela e para melhorar a detecção de clusterina e de isoformas dela, kit e complexo
JP7671956B2 (ja) 抗原の測定方法及び固相化抗体の製造方法
NZ736200B2 (en) Specific detection of clusterin isoforms
KR20110115292A (ko) 폐암 진단용 Ｘａｇｅ－１ｄ 마커 및 이를 이용한 진단 키트
KR101174736B1 (ko) 대장암 진단 방법
JP2024066398A (ja) がんの検査方法、試薬、キット及び装置
JP2025181797A (ja) アルツハイマー病の検査方法およびアルツハイマー病の検査キット
WO2007038579A1 (en) Bax expression predicts hematologic disease response to treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190408

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190408

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200518

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200817

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210129

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210129

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210208

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210630

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210824

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210917

R150 Certificate of patent or registration of utility model

Ref document number: 6948265

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250